Bookrunners Jefferies and J.P. Morgan assist with sale of common stock
By Devika Patel
Knoxville, Tenn., June 15 - Aegerion Pharmaceuticals, Inc. priced a $50.15 million public sale of stock with a $7.52 million greenshoe in a prospectus supplement filed Friday with the Securities and Exchange Commission. The deal was announced Wednesday.
The company will sell 3.4 million common shares at $14.75 apiece. The price per share is a 0.2% premium to the June 14 closing share price of $14.72.
Jefferies and J.P. Morgan are the joint bookrunning managers, and Leerink Swann, Canaccord Genuity and Needham & Co. are co-managers.
Settlement is expected June 19.
Proceeds will be used to advance the clinical development of lomitapide, as well as for working capital, capital expenditures and general corporate purposes.
The specialty pharmaceutical company is based in Cambridge, Mass.
| Issuer: | Aegerion Pharmaceuticals, Inc.
|
| Issue: | Common shares
|
| Amount: | $50.15 million
|
| Greenshoe: | $7,522,500
|
| Shares: | 3.4 million
|
| Price: | $14.75
|
| Warrants: | No
|
| Bookrunners: | Jefferies and J.P. Morgan
|
| Announcement date: | June 13
|
| Pricing date: | June 15
|
| Settlement date: | June 19
|
| Stock symbol: | Nasdaq: AEGR
|
| Stock price: | $14.72 at close June 14
|
| Market capitalization: | $317.57 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
